Summary
The AI claims include multiple statements about indications/mechanism and acute vs long-term effects that are not supported by the provided FDA label excerpts. The label excerpts you supplied focus on pregnancy/teratogenicity and hepatotoxicity/pancreatitis, and do not substantiate the AI’s broader efficacy/usage assertions. Multiple unsupported claims create a low-confidence mismatch.
Category Scores
Accurate Statements
In the body, divalproex breaks down into valproate.
Not supported by the provided label excerpts.
Unsupported Statements
Divalproex is an anticonvulsant medicine.
The provided label excerpts do not contain this indication statement.
Valproate helps stabilize electrical activity in the brain.
No mechanism-of-action support appears in the provided label excerpts.
Divalproex is used to treat conditions related to abnormal brain signaling, including seizures.
No seizure-related indication language is provided in the supplied label excerpts.
Divalproex is used to treat certain mood disorders.
No mood-disorder indication language is provided in the supplied label excerpts.
Divalproex helps reduce the frequency and severity of some seizure types.
No efficacy statements regarding seizure frequency/severity are provided in the supplied label excerpts.
Divalproex reduces the frequency and severity of some seizure types by changing how neurons communicate.
Mechanism and efficacy are not supported by the provided label excerpts.
Divalproex provides better seizure control for people with the specific seizure diagnoses for which the drug is prescribed.
No comparative efficacy or 'specific diagnoses' support is present in the provided label excerpts.
Divalproex is used for mood stabilization.
No mood-stabilization indication language is provided in the supplied label excerpts.
Divalproex can be prescribed for bipolar disorder.
No bipolar-disorder indication language is provided in the supplied label excerpts.
Divalproex can reduce manic symptoms.
No manic-symptom efficacy language is provided in the supplied label excerpts.
Divalproex can help prevent mood episodes in people who are appropriate candidates for the medication.
No mood-episode prevention language is provided in the supplied label excerpts.
Divalproex is not a pain reliever.
No statement about being/not being a pain reliever appears in the provided label excerpts.
Divalproex is not a quick-acting rescue medicine for emergencies like a short-term migraine triptan.
The provided label excerpt only states there is no evidence for acute treatment of migraine headaches; it does not support the comparison to 'triptan' or 'rescue medicine' wording.
The effects of divalproex are aimed at long-term control of seizure activity or mood stability rather than immediate symptom relief.
The provided label excerpts do not support this generalization about seizures or mood stability timing.
Contradictions
Important Omissions
The AI response does not mention the FDA Boxed Warning content (hepatotoxicity/fatalities, increased risk in children under 2, teratogenicity/neural tube defects, pancreatitis, and associated monitoring/discontinuation guidance).
Importance:
High
The AI response does not state pregnancy-teratogenic risk counseling language from the label (benefits weighed against fetal risk; avoid use except essential; neural tube defect risk).
Importance:
High
The AI response does not include contraindication highlights from the provided label excerpts (hepatic disease/significant hepatic dysfunction; hypersensitivity; urea cycle disorders).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response omits major on-label safety communications from the provided Boxed Warning (fatal hepatotoxicity, teratogenicity including neural tube defects, and pancreatitis) and makes several unsupported claims about indications/efficacy/timing that are not grounded in the supplied label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most indication/mechanism/efficacy/timing statements are unsupported by the provided FDA label excerpts; major Boxed Warning safety information is omitted.
Suggested Improvement
Limit claims to the provided label excerpts (or supply the full relevant label sections), and explicitly include Boxed Warning and key pregnancy/hepatotoxicity/pancreatitis monitoring/discontinuation language.